Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

Affiliations

• ¹ Cardio-Oncology Service, Royal Brompton Hospital and Imperial College, London, UK.
• ² Duke Cancer Institute, Duke University, Durham, NC, USA.
• ³ Breast Unit, Royal Marsden Hospital, Surrey, UK.
• ⁴ Department of Oncology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.
• ⁵ Division of Medical Oncology, Sinai Health System, Mount Sinai Hospital, Toronto, Canada.
• ⁶ UMR-S 942, Paris University, Cardiology Department, Lariboisiere Hospital, AP-HP, Paris, France.
• ⁷ Department of Translational Medical Sciences and Interdepartmental Center for Clinical and Translational Research (CIRCET), Federico II University, Naples, Italy.
• ⁸ Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
• ⁹ Cardio-Oncology Program, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.
• ¹⁰ Department of Cardiology, Medical University of Vienna, Vienna, Austria.
• ¹¹ Department of Clinical Oncology, Royal Marsden Hospital and Institute of Cancer Research, London, UK.
• ¹² Department of Medical Imaging and Radiation Sciences, Monash University and Department of Medicine, Melbourne University, Melbourne, Australia.
• ¹³ Department of Cardiology, National University Heart Centre, Singapore, National University Health System, Singapore, Singapore.
• ¹⁴ Division of Cardiology and Metabolism, Department of Cardiology, Charité and Berlin Institute of Health Center for Regenerative Therapies (BCRT) and DZHK (German Centre for Cardiovascular Research), partner site Berlin and Department of Cardiology, Charité Campus Benjamin Franklin, Berlin, Germany.
• ¹⁵ Department of Cardiology and Pneumology, University of Goettingen Medical Center, Goettingen, Germany.
• ¹⁶ German Center for Cardiovascular Research (DZHK), partner site Goettingen, Goettingen, Germany.
• ¹⁷ Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany.
• ¹⁸ First Department of Medicine - Cardioangiology, Charles University Prague, Medical Faculty and University Hospital Hradec Kralove, Prague, Czech Republic.
• ¹⁹ MedStar Heart and Vascular Institute, Georgetown University, Washington, DC, USA.
• ²⁰ Ted Rogers Program in Cardiotoxicity Prevention and Joint Division of Medical Imaging, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada.
• ²¹ University of Pennsylvania, Philadelphia, PA, USA.
• ²² Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
• ²³ Sechenov Medical University, Moscow, Russia.
• ²⁴ Department of Community Cardiology, Tel Aviv Jaffa District, Clalit Health Fund and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
• ²⁵ School of Medicine and Public Health, University of Newcastle and "Cancer and the Heart" Program, Hunter New England LHD, Newcastle, Australia.
• ²⁶ Cardio-Oncology, Department of Cardio-Pneumology, University of São Paulo, São Paulo, Brazil.
• ²⁷ Santa Cardio-Oncology, Santa Casa de São Paulo and Rede Dor São Luiz, São Paulo, Brazil.
• ²⁸ Barts Heart Centre and University College London, London, UK.
• ²⁹ Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy.
• ³⁰ University of Cyprus Medical School, Nicosia, Cyprus.
• ³¹ Cardio-Oncology Clinic, Heart Failure Unit, "Attikon" University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
• ³² Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
• ³³ Cardiology Division, Internal Medicine Department, American University of Beirut Medical Center, Beirut, Lebanon.
• ³⁴ Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.
• ³⁵ Cardioncology Unit, European Institute of Oncology, IRCCS, Milan, Italy.
• ³⁶ Stanford University School of Medicine, Stanford, CA, USA.
• ³⁷ Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
• ³⁸ Vanderbilt University Medical Center, Nashville, TN, USA.
• ³⁹ National Amyloidosis Centre, University College London, London, UK.
• ⁴⁰ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ⁴¹ Department of Haematology, Hammersmith Hospital, Imperial College, London, UK.
• ⁴² Department of Haematological Medicine, King's College Hospital, London, UK.
• ⁴³ University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.
• ⁴⁴ University of Warwick, Warwick, UK.
• ⁴⁵ Pharmacology, Centre of Clinical and Experimental Medicine, IRCCS San Raffaele Pisana, Rome, Italy.
• ⁴⁶ Faculty of Medicine and Serbian Academy of Sciences and Arts, University of Belgrade, Belgrade, Serbia.
• ⁴⁷ Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, Romania.
• ⁴⁸ University of Medicine Carol Davila, Bucharest, Romania.
• ⁴⁹ Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany.
• ⁵⁰ Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
• ⁵¹ Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, Liverpool, UK.
• ⁵² Cardiology Service, Cardio-Oncology Unit, La Paz University Hospital and IdiPAz Research Institute, Ciber CV, Madrid, Spain.
• ⁵³ Department of Cardiology, The Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, UK.
• ⁵⁴ Cardio-Oncology Center of Excellence, Washington University in St Louis, St Louis, MO, USA.